Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIT personalized therapy for advanced kidney cancer
2014-004830-25Phase 2Terminated
- Sponsor
- Oslo University Hospital
- Start
- May 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib, everolimus, temsirolimus, pazopanib, sorafenib and 7 more in kidney cancer and renal cell carcinoma (RCC) (2 arms), sponsored by Oslo University Hospital. Started May 2015; status: terminated.
02
Drugs
cabozantinibeverolimustemsirolimuspazopanibsorafenib
03
Conditions
kidney cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2014-004830-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004830-25.